Moderna and Merck Plan Broader Cancer Vaccine Tests After Phase 3 Success

Melanoma result opens a wider question

Moderna and Merck are looking beyond melanoma after their personalized cancer vaccine intismeran succeeded in a pivotal Phase 3 trial. At the ESMO meeting in Madrid, Moderna CEO Stéphane Bancel told STAT the companies are preparing to test the vaccine in other cancers. The announcement points to a familiar ambition in cancer medicine: take a treatment that appears to work in one disease and find out whether its underlying approach can help patients with others.

That ambition is easier to state than to deliver. Cancers can differ in the mutations they carry, the way they grow, and how they interact with the immune system. A vaccine tailored to an individual tumor is designed around some of those differences. But success in melanoma doesn’t establish that the same strategy will produce a meaningful benefit elsewhere. Each new cancer type will raise its own questions about which patients might respond, how the vaccine should be used, and what evidence would show that it helps.

What a personalized cancer vaccine does

Unlike a preventive vaccine, which aims to reduce the chance of an infection before it occurs, a therapeutic cancer vaccine is intended to help the immune system recognize and attack an existing cancer. A personalized approach starts with information about a patient’s tumor and uses it to select targets for a vaccine made for that individual. The aim is to direct immune cells toward features of the cancer that may distinguish it from healthy tissue.

That process makes the treatment concept different from a single drug that can be given in the same form to a broad population. Personalization can make the target more relevant to a particular tumor, but it also adds practical and scientific demands. The team must identify suitable targets, produce the vaccine, and deliver it within a treatment plan whose timing matters. The general idea is compelling. Whether the resulting treatment improves outcomes is a separate question that clinical trials have to answer.

And that’s the part most people overlook: a personalized design doesn’t guarantee a personalized success. Tumors can vary within a single patient, and their biology can change over time. Some may not present the selected targets in a way the immune system can effectively recognize. Those are general challenges for this class of treatment; the source doesn’t say how the companies plan to address them in other cancers.

Phase 3 success and the road to FDA review

Bancel said they’re racing to submit intismeran for FDA approval, which he expects in 2027. That expectation is a company executive’s outlook, not an approval decision. The companies will need to submit their evidence for review, and the agency will assess the data and the proposed use before deciding whether the vaccine can be marketed for that indication.

A pivotal Phase 3 result carries weight because it comes from a late-stage test intended to establish whether a treatment can provide a meaningful benefit in its studied setting. But the article doesn’t provide the trial’s design, the size of the benefit, the safety findings, or the details of the patient group. Without those details, readers can’t judge how large or durable the effect was, or how it compares with available care. “Succeeded” signals a positive result; it doesn’t, by itself, explain the result’s clinical importance.

The distinction matters in cancer research, where a promising signal can be shaped by the population enrolled, the treatment given alongside the experimental vaccine, and the outcome chosen to measure success. Those details help doctors and patients understand what a trial actually demonstrated. They also help reviewers evaluate whether the evidence supports the intended use.

Why other cancers will require new evidence

The next question is whether the melanoma result can translate to other cancers. The companies are preparing to test intismeran in other cancers, but Bancel’s comments don’t identify which ones, when those studies will begin, or how they’ll be designed. The expansion is therefore a plan to investigate a possibility, not evidence that the vaccine already works beyond melanoma.

Different cancers may present different targets and different barriers to an immune response. A vaccine strategy could perform well in one setting and prove less useful in another, even if the underlying technology is similar. Researchers will need evidence for each intended use, including whether the treatment helps patients in that specific disease and how its benefits compare with its risks and practical burdens.

If you’re working in this space, the key question isn’t simply whether the platform can be adapted. It’s whether the adaptation produces a treatment effect that matters to patients. That requires more than showing that a vaccine can be made for another tumor; it requires clinical evidence that the approach changes outcomes in that cancer.

What the next steps could show

This is more significant than it looks because the melanoma trial may serve as an important test of whether personalized cancer vaccines can move from a promising idea toward an established treatment. Yet one successful trial can’t settle the broader case. The planned studies will show whether the companies can extend the approach across diseases with distinct biology, while the FDA review will assess the evidence for the melanoma use described here.

For now, the story has two separate milestones: a reported Phase 3 success in melanoma and plans to test intismeran in other cancers. The first could support an application, which Bancel expects in 2027. The second remains a research question. Any broader claim will have to wait for results from those studies—and for enough detail to judge what the results mean.